Normalization of defective t cell responsiveness through...

Details Normalization of defective t cell responsiveness through... Normalization of defective t cell responsiveness through...

A - Human Necessities

61

K

A61K 35/28 (2006.01) A61K 31/56 (2006.01) A61K 35/14 (2006.01) A61K 38/08 (2006.01) A61K 38/09 (2006.01) A61K 38/18 (2006.01) A61K 38/19 (2006.01) A61K 38/20 (2006.01) A61K 38/24 (2006.01) A61K 39/00 (2006.01) A61P 37/04 (2006.01)

Patent

CA 2462671

The present disclosure provides methods for the treatment and potential alleviation of autoimmune diseases and allergies in a patient. This is accomplished by deleting at least most of the existing T cell population and reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system and to supply normal T cells to the patient or to replace existing aberrant T cells. In a preferred embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In a preferred embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

L'invention concerne des procédés de traitement et d'atténuation potentielle de maladies auto-immunes et d'allergies chez un patient. On peut obtenir un tel résultat en supprimant au moins la majeure partie des lymphocytes T et en réactivant le thymus. On peut éventuellement administrer des cellules souches embryonnaires hématopoïétiques, autologues, syngéniques, allogéniques ou xénogéniques afin d'accélérer la vitesse de régénération du système immunitaire du patient et de fournir des lymphocytes T normaux au patient ou de remplacer les lymphocytes T anormaux existants. Selon un mode de réalisation favori, les cellules souches embryonnaires hématopoïétiques sont des CD34+. Le thymus du patient est réactivé par l'interruption de la signalisation induite par un stéroïde sexuel au thymus. Selon un mode de réalisation favori, cette interruption est réalisée grâce à l'administration d'agonistes LHRH, d'antagonistes LHRH, d'anticorps récepteurs anti-LHRH, de vaccins anti-LHRH ou de combinaisons de ceux-ci.

Affiliated with

Also associated with

Rating

Normalization of defective t cell responsiveness through... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Normalization of defective t cell responsiveness through..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Normalization of defective t cell responsiveness through... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2075348